Download Cancer Program Annual Report

2 0 1 5
2015
Cancer
Program
ANNUAL REPORT
2015 Chairperson’s Report –
HCGH Cancer Program Annual Report
Reflecting back on what we have accomplished in HCGH’s cancer program in 2015, we certainly
have much to be proud of. Our sights are always set on high quality care, patient safety and bringing
innovations in cancer care to our program, and 2015 was a year of growth for our program in
several areas.
This year, HCGH’s cancer program received a three-year accreditation with silver level
commendation as a Comprehensive Community Cancer Program (CCCP) from the American
College of Surgeons’ (ACoS) Commission on Cancer (CoC), an accomplishment of which we are
most proud. This recognition is another sign that HCGH’s cancer program continues to deliver
high-level care to those who turn to our oncology specialists.
Sally Cheston, M.D.
Central Maryland Radiation Oncology is a partnership between Howard County General Hospital,
Johns Hopkins Medicine and the University of Maryland Medical System. With this relationship,
we are able to adopt and implement new treatment modalities “ahead of the curve” of communitybased radiation oncology facilities which do not have an academic affiliation. For instance, the
overwhelming majority of our breast cancer patients are now treated with hypo-fractionated
radiation therapy, delivering the course of therapy with one half to one third fewer treatments than
conventional therapy, while providing equal effectiveness and less toxicity. Cancer care in Howard
County is significantly enhanced by this partnership.
Our commitment to serving patients and our surrounding community also continued in 2015.
The Central Maryland Oncology Practice recently introduced a new resource support program
for patients to address some of their quality of life issues. The support program assists oncology
patients with medical and non-medical issues that arise so that they can focus on their treatments.
Comprehensive support services include prescription assistance, transportation to medical
treatments, utility services, meal delivery, medical assistance and counseling services.
Finally, HCGH, in partnership with Central Maryland Radiation Oncology, medical oncology and
Johns Hopkins Community Physicians (JHCP), has been working to provide select patients with
a survivorship visit at the culmination of cancer treatment. As our survivorship program continues
to be developed in the coming year, we look forward to offering more patients with this visit, which
provides a documented summary of their cancer treatment as well as recommendations for followup, ensuring that our cancer survivors thrive in their lives after cancer.
As we continue to grow the HCGH cancer program and our services, we are providing our
community with the highest level of cancer care as well as a future full of new possibilities.
Sally Cheston, M.D.
Radiation Oncology, Cancer Committee Chair
2
Cancer Conference Report
Cancer conferences improve the care of patients with cancer by providing multidisciplinary treatment planning and
contribute to physician and allied medical staff education.
The HCGH Cancer Program currently offers four cancer conferences. Cases are presented at a point when patient care
management can be directly influenced by the discussion. Each discussion includes the patients’ medical history; physical
findings; diagnostic, pathologic and operative findings; staging; and treatment options. Discussions also include national
evidence-based guidelines, protocol updates, literature reviews and presentation of cancer registry data.
General
Conference
2014
Breast
Conference
Thoracic
Conference
Genito-Urinary
Conference
Day
2nd & 4th Friday
Every Tuesday
3rd Friday
1st Tuesday
Time
12:15 p.m.
7:30 a.m.
7:30 a.m.
12:00 p.m.
Location: (Medical Pavilion)
Suite G010
Suite G010
Suite G010
Suite G030
19
51
10
12
# of Meetings
All Conferences
Combined
92
Attendance by Surgeon
5 (11%)
50 (98%)
7 (70%)
12 (100%)
74 (80%)
Attendance by Diag. Radiology
10 (44%)
51 (100%)
4 (40%)
N/A*
65 (81%)*
Attendance by Pathology
17 (78%)
51 (100%)
10 (100%)
N/A*
78 (98%)*
Attendance by Med. Oncology
19(100%)
51 (100%)
10 (100%)
12 (100%)
92 (100%)
Attendance by Rad. Oncology
18 (89%)
50 (98%)
10 (100%)
12 (100%)
90 (98%)
Total Attendance
217
833
94
146
1290
Average Attendance
11
16
9
12
14
Total # of Patients Discussed
63
287
48
61
459
Average # of Cases Per Mtg.
3
6
5
5
5
*Radiologists and Pathologists are not required to attend the GU conferences. Average attendance based on 80 total meetings.
CASE DISTRIBUTION BY CONFERENCE
General
Site
Breast
Thoracic
Cases
Site
Cases
Lung
17
Breast
287
Colorectal
9
NHL/Hodgkin
Breast
Genitourinary
Site
Cases
Site
Cases
Lung
31
Prostate
48
Dx. Unk.
7
Bladder
8
8
Mets.
6
Kidney
1
4
Benign
2
Met. Melanoma
1
Unk. Primary
4
NHL
1
Epididymis
1
Other Digestive
4
Thymoma
1
Testis
2
Female Genital
3
Pancreas
3
Skin-Melanoma
3
Liver
2
Urinary
2
Other
TOTAL
4
63
287
48
All conferences are coordinated through the Oncology Data Office. For additional information, contact Sheryl Daugherty at [email protected]
or 410-740-7956 or Sharon Tunney at [email protected] or 410-720-8515.
3
61
Cancer Registry Report
Hospital-based cancer registries serve as the nation’s primary source of oncology statistics. This
comprehensive collection of patient data facilitates comparisons between individual facilities
and the state, or the nation as a whole. As with all cancer registries, the role of the Oncology
Data Office at HCGH continues to grow and evolve. With advances in cancer related research,
technology and treatments, the registry collects more detailed information than ever before.
Information collected and analyzed includes demographic, personal and family histories, risk
factors, diagnostic procedures, site and histology, tumor markers, prognostic indicators, staging,
treatment, follow-up and survival data for each case.
The Oncology Data Office at Howard County General Hospital, a part of the Health
Information Management Department, collects data on all cancer patients diagnosed and/or
treated at this facility.
In 2014, 623 analytic cases were accessioned to the registry’s database (Table 1, page 5). This is a
5.75% decrease from 2013. Over the past year, the number of new breast cancer cases decreased
8.52% from 176 in 2013 to 161 in 2014. Breast cancer remained the most frequently seen
primary site at Howard County General, making up 25.84% of the entire analytic case load.
The second most frequently seen primary site in 2014 was colorectal with 77 cases (12.40% of
the total caseload). This represents an increase of 26.23% over the 61 colorectal cancer cases
accessioned in 2013.
The other top primary sites seen at the hospital were lung, prostate, urinary bladder and nonHodgkin lymphoma. The number of lung cancer cases decreased by 29.67% from 91 cases in
2013 to 64 in 2014. Prostate cases decreased from 35 to 29 over the past year. This is a decrease
of 17.14%. Bladder cases decreased from 38 cases in 2013 to 29 in 2014. This is a decrease of
23.68%. Non-Hodgkin lymphoma cases increased by 3.57% from 28 cases in 2013 to 29 cases
in 2014. For 2014, lung cancer cases made up 10.27% of the total analytic caseload. Prostate,
bladder and non-Hodgkin lymphoma cases were tied at 4.65% of the total analytic caseload.
When compared to state and national statistics, HCGH continued to see breast and colorectal
cancer cases as a significantly higher percentage of its total caseload. The incidences of bladder
cancer cases were slightly higher at HCGH than for the state of Maryland and equal to that of the
national data. The incidence of prostate and lung cancer cases were significantly lower than those
of the state and nation (Table 2, page 6).
Individual registries help hospital physicians and administrators track quality of care and treatment
by monitoring compliance with national evidence-based guidelines. Registry data is also used by
the hospital for cancer conference presentations, administrative reports, to evaluate staffing and
equipment needs, and guide the development of educational and screening programs for both
patients and the community.
The Oncology Data Office staff also compiles the required documentation to insure the HCGH
oncology program’s compliance with all standards established by the American College of
Surgeons (ACoS) Commission on Cancer (CoC) to maintain its accreditation as a Comprehensive
Community Cancer Program (CCCP).
For more information about the HCGH Cancer Registry, please call 410-740-7956.
4
TABLE 1
HCGH 2014 SITE DISTRIBUTION TABLE – ANALYTIC CASES
Sex
Primary Site
AJCC Stage at Dx
Cases
M
F
0
I
II
III
IV
N/A UNK
Oral Cavity, Pharynx
Salivary Gland
Floor of Mouth
Tonsil
10
6
1
3
4
2
0
2
6
4
1
1
0
0
0
0
2
1
1
0
1
1
0
0
0
0
0
0
4
2
0
2
0
0
0
0
3
2
0
1
Digestive Organs
Esophagus
Stomach
Small Intestine
Colon
Rectosigmoid / Rectum
Anus & Anal Canal
Liver & Intrahep Bile Ducts
Gallbladder
Other Biliary
Pancreas
Other Digestive Organs
142
6
12
7
58
19
1
10
4
3
19
3
80
3
7
5
31
11
0
8
0
3
10
2
62
3
5
2
27
8
1
2
4
0
9
1
4
0
0
0
4
0
0
0
0
0
0
0
33
3
3
1
12
2
1
3
3
0
5
0
35
1
2
1
17
6
0
2
0
1
5
0
30
0
3
2
13
7
0
1
0
1
3
0
29
1
3
3
10
1
0
4
1
0
6
0
4
0
0
0
0
0
0
0
0
1
0
3
7
1
1
0
2
3
0
0
0
0
0
0
Respiratory System
Nose, Nasal Cavity & Middle Ear
Larynx
Lung & Bronchus
Trachea, Mediastinum, Other Resp.
69
1
2
64
2
34
1
1
31
1
35
0
1
33
1
0
0
0
0
0
15
0
0
15
0
5
0
0
5
0
18
0
0
16
3
30
1
2
27
0
0
0
0
0
0
1
0
0
1
0
Skin (Excludes Squamous & Basal Cell)
Melanoma
Other Non-Epithelial Skin
30
27
3
16
14
2
14
13
1
10
10
0
10
10
0
3
3
0
2
1
1
2
2
0
1
0
1
2
1
1
3
2
1
0
2
0
1
0
0
0
Breast
161
4
157
22
74
48
10
5
0
2
Female Genital Organs
Cervix
Uterus
Ovary
Other Female Genital Organs
26
2
17
6
1
0
0
0
0
0
26
2
17
6
1
0
0
0
0
0
11
1
8
1
1
1
0
0
1
0
5
0
4
1
0
7
1
3
3
0
0
0
0
0
0
2
0
2
0
0
Male Genital Organs
Prostate
Testis
Other Male Genital Organs
36
29
6
1
36
29
6
1
0
0
0
0
0
0
0
0
14
8
6
0
15
15
0
0
1
1
0
0
5
5
0
0
1
0
0
1
0
0
0
0
Urinary Tract
Urinary Bladder
Kidney & Renal Pelvis
33
29
4
27
23
4
6
6
0
19
18
1
7
5
2
5
5
0
1
0
1
1
1
0
0
0
0
0
0
0
Brain / Other Nervous System
Meninges/Brain/CNS Benign & Borderline
Brain, Malignant
27
22
5
10
7
3
17
15
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27
22
5
0
0
0
Endocrine System
Thyroid
Other Endocrine including Thymus
17
11
6
3
1
2
14
10
4
0
0
0
8
8
0
0
0
0
2
2
0
1
1
0
6
0
6
0
0
0
Lymphoma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
32
3
29
16
1
15
16
2
14
0
0
0
5
0
5
7
2
5
9
0
9
9
1
8
0
0
0
2
0
2
Myeloma
4
3
1
0
0
0
0
0
4
0
Leukemia
Lymphocytic
Myeloid & Monocytic
15
6
9
7
4
3
8
2
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
6
9
0
0
0
Kaposi Sarcoma
1
1
0
0
0
0
0
0
1
0
Soft Tissue Including Heart
Unknown & Other Primary Site
17
11
6
0
0
0
0
0
17
0
ALL SITES
623
254
369
55
181
120
79
93
76
19
Abbreviations: M=male, F=female, UNK=unknown or unstageable, N/A=not applicable. Carcinoma in-situ/CIN III of the cervix is not included.
5
TABLE 2
HCGH Top 5 Site Comparison: 2014 Analytic Cases
Bladder
US
MD
Site
Prostate
HCGH
Lung
Colorectal
Breast
0 51015202530
Percent of Total Caseload
US and MD statistics from ACS Facts and Figures
TABLE 3
HCGH 2014 Analytic Cases – Age by Sex Distribution
90+
Female
Male
80-89
Age at Diagnosis
70-79
60-69
50-59
40-49
30-39
0-29
0 1020 30405060708090100
Number of Cases
6
TABLE 4
HCGH 2014 Analytic Cases – Race Distribution
4%
3% 2%
Caucasian
19%
African American
Oriental
Asian Indian/Pakistani
Other
72%
Cancer Program Practice Profile Report (CP3R)
Breast, Cervix, Colon, Endometrium, Gastric, Lung, Ovary and
Rectal Cases Diagnosed 2011 – 2013
Ongoing quality reviews monitor HCGH’s compliance with nationally established evidence-based treatment guidelines for
the management of care for cancer patients. This review includes 20 measures and compares our performance rate with those
from our American Cancer Society (ACS) division, our census region, all CoC (Commission on Cancer)programs accredited
at the same level as we are (CCCP – Comprehensive Community Cancer Program), all CoC accredited hospitals in the state of
Maryland and all CoC accredited programs in the entire U.S. This data is compiled by the National Cancer Data Base (NCDB)
using information submitted by cancer registries at all CoC accredited hospitals. An accountability measure is the standard of care
based on clinical trial evidence. They are used for public reporting, payment incentive programs, and the selection of providers by
consumers, health plans, or purchasers. A quality improvement measure is one that demonstrates good practice but is not based
on clinical trial evidence. They are intended for internal monitoring of performance within an organization. Surveillance measures
are used to monitor patterns and trends of care in order to guide decision-making and resource allocation.
Performance Rate (%)
Title
Measure Definition
2011
2012
2013
Breast Cancer Measures
BCS
Breast conservation surgery rate for women with AJCC clinical stage 0, I, or
II breast cancer.(Surveillance)
75.5%
(71/94 cases)
70.2%
(80/114 cases)
75.5%
(77/102 cases)
nBx
Image or palpation-guided needle biopsy (core or FNA) of the primary site is
performed to establish diagnosis of breast cancer. (Quality Improvement)
91.8%
(89/97 cases)
95.5%
(84/88 cases)
85.1%
(97/114 cases)
Table continued on page 8
7
Performance Rate (%)
Title
Measure Definition
2011
2012
2013
100%
(41/41 cases)
96.3%
(52/54 cases)
92.3%
(60/65 cases)
Breast Cancer Measures
HT
Tamoxifen or third generation aromatase inhibitor is considered or
administered within 1 year (365 days) of diagnosis for women with AJCC T1c,
or stage IB-III hormone receptor positive breast cancer. (Accountability)
MASTRT
Radiation therapy is considered or administered following any mastectomy
within 1 year (365 days) of diagnosis of breast cancer for women with >= 4
positive regional lymph nodes. (Accountability)
100%
(4/4 cases)
100%
(6/6 cases)
100%
(3/3 cases)
BCSRT
Radiation is administered within 1 year (365 days) of diagnosis for women
under the age of 70 receiving breast conservation surgery for breast cancer.
(Accountability)
97.6%
(40/41 cases)
93.2%
(41/44 cases)
92.7%
(51/55 cases)
MAC
Combination chemotherapy is considered or administered within 4 months
(120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage II or
III hormone receptor negative breast cancer. (Accountability)
100%
(11/11 cases)
87.5%
(7/8 cases)
100%
(6/6 cases)
CERRT
Radiation therapy completed within 60 days of initiation of radiation among
women diagnosed with any stage of cervical cancer (Surveillance)
100%
(1/1 cases)
No Data
(0 cases)
No Data
(0 cases)
CERCT
Chemotherapy administered to cervical cancer patients who received
radiation for stages IB2-IV cancer (Group 1) or with positive pelvic
nodes, positive surgical margin, and/or positive parametrium (Group 2)
(Surveillance)
100%
(1/1 cases)
No Data
(0 cases)
No Data
(0 cases)
CBRRT
Use of brachytherapy in patients treated with primary radiation with curative
intent in any stage of cervical cancer (Surveillance)
100%
(1/1 cases)
No Data
(0 cases)
No Data
(0 cases)
ACT
Adjuvant chemotherapy is considered or administered within 4 months (120
days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph
node positive) colon cancer (Accountability)
100%
(2/2 cases)
100%
(7/7 cases)
87.5%
(7/8 cases)
94.4%
(17/18 cases)
96.9%
(31/32 cases)
100%
(29/29 cases)
No Data
(0 cases)
100%
(1/1 case)
No Data
(0 cases)
33.3%
(2/6 cases)
100%
(4/4 cases)
85.7%
(6/7 cases)
No Data
(0 cases)
66.7%
(2/3 cases)
50%
(1/2 cases)
Cervical Cancer Measures
Colon Cancer Measures
12RLN
At least 12 regional lymph nodes are removed and pathologically examined
for resected colon cancer. (Quality Improvement)
ENDCTRT
Chemotherapy and/or radiation administered to patients with Stage IIIC or
IV Endometrial cancer (Surveillance)
Endometrial Cancer Measures
ENDLRC
Endoscopic, laparoscopic, or robotic performed for all Endometrial
cancer (excluding sarcoma and lymphoma), for all stages except stage IV
(Surveillance)
G15RLN
At least 15 regional lymph nodes are removed and pathologically examined
for resected gastric cancer. (Quality Improvement)
Gastric Cancer Measure
Lung Cancer Measures
10RLN
At least 10 regional lymph nodes are removed and pathologically examined
for AJCC Stage IA, IB, IIA, and IIB resected NSCLC. (Surveillance)
0%
(0/3 cases)
0%
(0/4 cases)
0%
(0/1 cases)
LNoSurg
Surgery is not the first course of treatment for cN2, M0 lung cases (Quality
Improvement)
100%
(6/6 cases)
50%
(1/2 cases)
100%
(4/4 cases)
LCT
Systemic chemotherapy is administered within 4 months to day
preoperatively or day of surgery to 6 months postoperatively, or it is
considered for surgically resected cases with pathologic lymph node-positive
(pN1) and (pN2) NSCLC. (Quality Improvement)
No Data
(0 cases)
100%
(5/5 cases)
No Data
(0 cases)
Ovarian Cancer Measures
OVSAL
Salpingo-oophorectomy with omentectomy, debulking/cytoreductive surgery,
or pelvic exenteration in Stages I-IIIC Ovarian cancer (Surveillance)
20%
(1/5 cases)
No Data
(0 cases)
No Data
(0 cases)
OVCT
Chemotherapy started within 42 days (before or after) the Date of Most
Definitive Surgery in Stages IA-IV Ovarian, Fallopian Tube, or Peritoneal
cancers (Surveillance)
40%
(2/5 cases)
0%
(0/1 cases)
0%
(0/1 cases)
100%
(1/1 cases)
100%
(10/10 cases)
83.3%
(5/6 cases)
Rectal Cancer Measure
RECRTCT
Preoperative chemo and radiation are administered for clinical AJCC T3N0,
T4N0, or Stage III; or Postoperative chemo and radiation are administered
within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC
T3N0, T4N0, or Stage III; or treatment is considered; for patients under the
age of 80 receiving resection for rectal cancer (Quality Improvement)
8
TABLE 5
Comparison of 2013 CoC CP3R Accountability Measures (Std. 4.4)
Performance Rate
100.00%
HCGH
80.00%
ACS Division
60.00%
Census Region
CoC Prgm Type
40.00%
Maryland
US
20.00%
0.00%
HT
MASTRT
BCSRT
MAC
ACT
MEASURE
TABLE 6
Comparison of 2013 CoC CP3R Quality Improvement Measures (Std. 4.5)
Performance Rate
100.00%
HCGH
80.00%
ACS Division
60.00%
Census Region
CoC Prgm Type
40.00%
Maryland
US
20.00%
0.00%
nBx
12RLN
G15RLN
LNoSurg
LCT
RECRTCT
MEASURE
TABLE 7
Comparison of 2013 CoC CP3R Surveillance Measures
100.00%
HCGH
Performance Rate
90.00%
80.00%
ACS Division
70.00%
Census Region
60.00%
CoC Prgm Type
50.00%
Maryland
40.00%
US
30.00%
20.00%
10.00%
0.00%
BCS
CERRT
CERCT
CBRRT ENDCTRT ENDLRC 10RLN
MEASURE
9
OVSAL
OVCT
Focus On Melanoma
The American Cancer Society estimates that over 73,000 cases of melanoma will be diagnosed in
2015. Melanoma most commonly starts in the skin, but it can start in other parts of the body. If
diagnosed early, melanoma is almost always curable.
Risk factors for melanoma include excessive exposure to ultraviolet radiation, pale skin, multiple or
unusual moles, history of severe sunburns, old age and a weakened immune system. Melanoma is
more than 20 times more common in Caucasians than in African Americans [Table 4, page 7].
Symptoms include change in the color or size of a mole, a new growth, or a sore that doesn’t heal.
Treatment for earlier stages of melanoma is usually surgical resection. More advanced stages
may receive other/additional treatments. This can include chemotherapy, radiation therapy,
immunotherapy or targeted therapy.
At HCGH, there were 61 new cases of melanoma in 2013-14. This includes 22 In Situ, or Stage 0
cases, 24 stage I, 7 Stage II, 3 Stage III, and 5 Stage IV cases [Table 8, below]. The site distribution
shows 22.41% of the cases were of the head and neck. Cases involving the skin of the torso made up
29.31%. 19.97% were from the upper extremity and 22.41% from the lower extremity [Table 9,
page 11]. The specific histology’s included melanoma NOS, superficial spreading melanoma,
nodular, lentigo maligna, acral lentiginous and spindle cell melanomas [Table 10, page 11].
Review of Analytic Cutaneous Melanoma Cases
A retrospective review of all patients diagnosed and/or treated at HCGH for newly diagnosed
melanoma between January 1, 2013 and December 31, 2014. This review included 61 cases and was
done to evaluate compliance with national evidence-based treatment guidelines.
TABLE 8
Total Number of Cases
Documented Breslow’s Thickness
Documented Ulceration Status
Documented Clinical N Stage
Documented Mitotic Rate
Documented Regression Status
Stage 0
Stage I
Stage II
Stage III
Stage IV
22
24
7
3
5
N/A
24
7
3
1
17
23
6
3
3
22
24
7
3
3
N/A
21
5
3
1
13
23
4
3
1
N/A
23
4
2
1
Pathologic Exam of Lymph Nodes
1
6
5
3
0
– Positive Lymph Nodes
0
0
0
3
0
Surgical Resection
22
24
7
3
1
– Clear Margins
22
24
7
3
0
Documented Vertical Growth Status
10
TABLE 9
HCGH 2013-14 Analytic Cutaneous Melanoma Site Distribution
6.90%
22.41%
Head and Neck
Trunk
22.41%
Upper Limb/Shoulder
Lower Limb/Hip
Skin, NOS
29.31%
18.97%
TABLE 10
HCGH 2013-14 Analytic Melanoma by Histology
In Situ
Spindle Cell, NOS
Histology
Acral Lentginous
Lentigo Maligna
Nodular
Superficial Spreading
Melanoma, NOS
0.00% 10.00%20.00%30.00%40.00% 50.00%60.00%
Percent Caseload
11
The Year in Review
• Co-sponsored the Cancer Survivors Reception at the American Cancer Society’s Relay for Life.
HCGH was a corporate sponsor and sponsored a team, which raised over $14,000.
• Free monthly meeting space was provided for the American Cancer Society Leadership Council
and the prostate cancer support group.
• The hospital provided space for Nicotine Anonymous meetings every Sunday evening.
• Oral cancer awareness education is provided during our Smoke Free Lungs class as well as at
health fairs in the community.
• The Great American Smokeout, which provided tobacco prevention information to more than
100 staff and visitors, was held in November in the HCGH main lobby. Pulmonary function tests
were also provided to 30 attendees.
• Through the “Let Go of Tobacco” program, HCGH provided patients in Labor & Delivery
with brochures listing local resources and websites available for smoking cessation. Another phase
provided anti-tobacco resources in local faith communities through the hospital’s Community
Cardiovascular Project. Parish-based volunteer nurses were provided with posters and brochures
on smoking cessation to share while screening for hypertension. Tobacco prevention information
was distributed to Maternal Child Health classes. Over 1,600 packets of information were
distributed through this program.
• Twenty-six prostate cancer screenings were performed by urologists at the HCGH Wellness
Center in April at the annual Topic of Cancer event.
• Distributed free colorectal cancer screening kits to the community at the Topic of Cancer event.
• In May, 49 skin cancer screenings were performed at the HCGH Wellness Center.
• Provided information on cancer risk reduction and the importance of early detection at health
fairs throughout the year.
• The hospital’s Speakers Bureau filled numerous requests for presentations on cancer risk
reduction and the dangers of tobacco use.
• The Howard County Cancer and Smoke Free Tobacco Coalition was represented by a member
of HCGH’s Wellness Center Staff.
• The Howard Hospital Foundation raised over $217,000 for the Claudia Mayer/Tina
Broccolino Cancer Resource Center (CMTBCRC), including nearly $150,000 from fundraisers
including Blossoms of Hope events, the signature Autumn Extravaganza event, and many smaller
events hosted by community members and local organizations.
• Participated in the Latino Health Fair. Free screenings, information booths and physician
experts provided health information to over 300 attendees. Breast health, cancer prevention and
BMI screenings were provided by HCGH staff.
• HCGH was a sponsor of “Get Active Howard County,” an annual healthy lifestyle program.
• Co-sponsored the 50+ Expo for thousands of seniors. Breast health information, blood pressures,
BMI, pulmonary function tests, and other wellness programs were offered at Wilde Lake High
School in October.
12
• Approximately 1,700 BMI (Body Mass Index) screenings were performed in the community,
due to the relationship between obesity and increased cancer risk.
• The Cancer Resource Center continued to offer programs to cancer patients such as yoga,
quilting, knitting and crocheting, and acupuncture. Other support programs offered at
CMTBCRC were Qi Gong, the Caregivers Support Group, Together We Thrive, and Living
with Cancer.
• Smoke Free Lungs, a free quarterly program for those who want to quit using tobacco, provided
support and education to those in any stage of the quitting process.
• The annual Healthy Howard Day highlighted healthy lifestyles, physical activity and wellness.
HCGH provided more than 70 BMI measurements.
• In May, over 2,000 people attended the Howard County Public School System’s Employee/
Family Wellness Day. HCGH staffed this 3rd annual event and provided over 300 BMI
calculations.
• In June, the Howard County Men’s Health Fair featured health awareness programs specific to
men. BMI screenings were provided to 70 participants.
• Ten online video presentations were available to our community on YouTube. Breast cancer,
prostate cancer, bladder cancer and kidney cancer were discussed. Wellness Center seminars on
obesity in children were featured.
• The Claudia Mayer/Tina Broccolino Cancer Resource Center co-sponsored the 2nd annual
Surviving Survivorship: Living with Cancer event in October.
• Cervical cancer education and information on HPV was provided along with breast health
education sessions.
13
Programs and Support Groups for Patients and Their Families
Claudia Mayer/Tina Broccolino Cancer Resource Center (CMTBCRC) – Provides educational,
aesthetic, emotional, and psychosocial support services through center resources, which include
a lending library, ongoing classes and support programs for patients, families and caregivers, full
service salon, prosthesis specialist, Oncology Social Worker, navigation, acupuncture and therapeutic
massage. For more information, call 410-740-5858.
Volunteer Wig Salon – Appointment required. 410-740-5858.
Breast Cancer Support Group – Meets the third Wednesday of the month from 7-8:30 p.m. Free,
but registration is required. For more information, call 410-740-5858.
Caregivers Support Group – Meets the first Tuesday of each month from 3:30-4:30 p.m. or the
second Saturday of each month from 10:00-11:00 a.m. Free, but registration is required. Call
410-740-5858 for more information.
Living with Cancer – Designed to meet the needs of men and women diagnosed with stage 4 or
metastatic disease. Meets the 4th Thursday of each month from 7-8:30 p.m. Free, but registration is
required. For more information call 410-740-5858.
Together We Thrive – Support group for men and women diagnosed with cancer. Meets the first
Saturday of each month from 10:00-11:30 a.m. Free, but registration is required. Call
410-740-5858 for more information.
The Red Devils – Financial support for breast cancer patients, coordinated through the
CMTBCRC. 410-740-5858.
The Little Things 4 Cancer – Financial support for all cancer patients, coordinated through the
CMTBCRC. 410-740-5858.
Advance Directives – A quarterly class to educate patients, families and members of the community
about advance directives. Sponsored by CMTBCRC and the Wellness Center. Free, but registration
is required. For additional information call 410-740-7601.
Yoga for Patients, Caregivers and Survivors – Offered Tuesdays from 10-11:00 a.m. under the
leadership of an experienced and clinically trained instructor. For information or to register,
call 410-964-9100.
Knitting and Crocheting Group – For patients and survivors, meets weekly on Wednesdays from
10:00 a.m.-Noon. Free. 410-740-5858.
Quilting Group – For patients and survivors. Meeting the 2nd and 4th Tuesdays of each month,
1-3:00 p.m. Free. 410-740-5858.
Healing Point – Provides acupuncture, therapeutic massage, and family counseling. 410-964-9100.
Comfort Care – Specializing in lymphedema, compression and mastectomy products. Call Kristin
Hassed, orthotic fitter, at 410-828-0947.
Wigs and Hair Solutions – Specializing in custom fitted synthetic and human hair wigs.
410-720-8588.
14
Programs through ACS at Cancer Resource Center
Look Good Feel Better – This American Cancer Society program provides a free workshop led by a
licensed cosmetologist. Women undergoing cancer treatment learn to manage the appearance-related
side effects of cancer treatment and receive a complimentary bag of cosmetics. Meets monthly. To
register call the American Cancer Society at 888-535-4555.
Road to Recovery – Sponsored by the American Cancer Society, volunteer drivers will provide
transportation for cancer patients undergoing treatment. Call 888-227-6333.
Reach to Recovery – Sponsored by the American Cancer Society, this service matches patients with
a volunteer who will talk about coping with breast cancer diagnosis and treatment.
Other Community Resources
Colorectal Cancer Program (CRCP) – Offered through the Howard County Health Department,
provides free colonoscopies to residents over 50, or over 21 who have an increased risk and lack
health insurance or are underinsured. Diagnosis and treatment services available if needed.
410-313-4255.
Breast and Cervical Cancer Diagnosis and Treatment Program (BCCP) – Offered through
the Howard County Health Department, provides clinical breast exams, mammograms and pap
tests for women aged 40 and over who have a limited income, lack insurance, or are underinsured.
Diagnosis and treatment services are also provided if needed. 410-313-4255.
American Cancer Society – Offering information and community resources. 800-227-2345.
Gilchrist Hospice Care – Services for the terminally ill, their families, and the bereaved. Call
410-730-5072.
HCGH Wellness Center – Programs include screenings, health fairs, support groups and smoking
cessation classes. For information call 410-740-7601.
Bolduc Family Outpatient Center – Physical and occupational therapies for cancer patients,
including breast cancer specific rehabilitation, including lymphedema therapy. 443-718-3000.
Moveable Feast – A non-profit agency that provides food and nutritional support counseling for
cancer patients and their families. Free. 410-740-5858.
15
2015 Cancer Committee
Sally Cheston, M.D., Radiation Oncology,
Cancer Conference Coordinator, Chairperson
Carolina Collison, CRNP, Palliative Care
Andrew Morton, M.D., Diagnostic Imaging
Stanley Podlasek, M.D., Pathology
Sandy Roemer, RN, Community Education
Sheryl Daugherty, RHIT, CTR, Oncology
Program Coordinator
Adrienne Shepardson, PharmD, Pharmacy
Sandra Dawson, RHIA, Director, Health
Information Management
Teji Sastry, M.D., Medical Oncology, Cancer
Liaison Physician
Suzi Ford, American Cancer Society
Judy Siegelman, RN, OCN, Nurse Manager, 4
South
Leslie Hack, PA-C, Quality Review
Coordinator
Martha Koch, M.D., Colorectal Surgery
Kelly Marasco, PT, Outpatient Rehab
Michelle Morgan, Clinical Research
Amy Tissiere, LCSW-C, OSW-C, Oncology
Social Worker / CMTBCRC
Jim Young, Administration
Lisa Jacobs, M.D., Medical Director,
Breast Center